Stay up to date
recent news & press releases
NEW YORK — Exai Bio, a company recently spun out of the University of California San Francisco based on work in the lab of Hani Goodarzi, is working to develop blood-based tests for cancer early detection and potentially other applications, enabled by genome-wide analysis of small noncoding RNAs.
Formed about six months ago and funded by a $67.5 million Series A financing last December, Exai recently shared data at the American Association for Cancer Research annual meeting from a study of more than 10,000 samples. Researchers were able to validate an AI-based approach to determine a cancer's tissue-of-origin based on these transcriptomic signals, something crucial for multi-cancer screening assays.